Future studies in T2D models, including those using IDE-deficient mice, are necessary to distinguish the relative contributions of IDE inhibition and NLRP3 suppression and to evaluate the potential of ML345 as a dual-targeting therapy. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.